Menu

Continued Fallout from Macchiarini Misconduct

The sacked researcher and surgeon was not properly vetted by the Swedish institutions that hired him in 2010, according to an independent review panel. 

Sep 7, 2016
Bob Grant

PIXABAY, DEBORABALVESThe swath of destruction caused by the alleged misconduct and fraud of surgeon Paolo Macchiarini continues to widen, as an independent panel reviews his case. In a report released last week (August 31), investigators commissioned by the Karolinska University Hospital—where Macchiarini used to work—stated that both the hospital and the Karolinska Institute (KI) failed to heed warning signs that the artificial organ researcher’s skill and professionalism was not up to par with the reputation he had cultivated in the popular press.

“Macchiarini was recruited as a senior physician at the hospital even though there were strongly critical opinions from his previous employers,” the investigators wrote. “Group thinking, bandwagon effects, a very competitive care environment, many informal leaders and deficient knowledge of and respect for rules are some of the factors that may have contributed to the course of events.”

Two KI officials are suffering backlash from the Macchiarini case. Anders Hamsten, who had already resigned from the institute’s vice-chancellor position over his role in hiring Macchiarini, and Harriet Wallberg, who was president of KI when the surgeon was hired, were both dismissed from the panel that awards Nobel Prizes for Medicine, according to The Guardian. In addition, Wallberg was fired from her post as the chancellor of the Swedish Higher Education Authority on Monday (Sept 5).

Several investigations have probed the Macchiarini case, which involved three artificial trachea implantations he performed while at KI. The researcher’s employment was terminated by the hospital in late 2013, and KI followed suit in March of this year. The most recent investigation echoed allegations of misconduct, including Macchiarini’s apparent failure to secure appropriate and informed consent, provide for his patient’s safety, or obtain necessary ethical clearance for the operations. Macchiarini has maintaned his innocence throughout.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.